Dyne Therapeutics, Inc. DYN
Set alert
16.69 USD -0.35 -2.05%
At close · Oct 30
16.69 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
16.34 Day range 17.19
14.25 52-week range 26.78
- YTD
- -14.67%
- 1 year
- -29.13%
- Open
- 17.04
- Prev close
- 17.04
- Mkt cap
- 3.12B
- Vol
- 1.45M
- Avg vol
- 2.78M
- EPS
- -3.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 16.34
- High
- 17.19
- Forward P/E
- -5.04
- Beta
- 1.12
- Short ratio
- 7.94
- Inst. own
- 103.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 18.72
- 200-d avg
- 19.31
- 1y target
- 34.33
Key statistics
- Market cap
- 3.11B
- Enterprise value
- 2.52B
- Trailing P/E
- 0.00
- Forward P/E
- -5.04
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.94
- EPS (TTM)
- -3.30
- Beta
- 1.12
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -317.14M
- Total cash
- 898.48M
- Total debt
- 233.35M
- Return on equity
- -81.57%
- Shares outstanding
- 186.75M
- Short % of float
- 17.44%
- 50-day average
- 18.72
- 200-day average
- 19.31
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 34.33 +105.7% upside
Now 16.69
- Target (low)
- 10.00
- Target (mean)
- 34.33
- Target (high)
- 50.00
Ratings (0m) 17 15 buy · 1 hold · 1 sell
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell1
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.88189.
Financials — quick view
DYN Revenue — quarterly 0
DYN Net income — quarterly -178.56M
DYN EPS — quarterly -1.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.90728 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -0.74878 | -1.08 | -0.33 | -44.23% |
| May 11, 2026 | Mar 31, 2026 | -0.77229 | -0.73 | +0.04 | +5.48% |
| Mar 2, 2026 | Dec 31, 2025 | -0.74 | -0.76 | -0.02 | -2.70% |
| Nov 5, 2025 | Sep 30, 2025 | -0.81 | -0.76 | +0.05 | +6.17% |
| Jul 28, 2025 | Jun 30, 2025 | -0.99 | -0.97 | +0.02 | +2.02% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Oppenheimer | down | Outperform | Perform |
| Sep 30, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 30, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 29, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Sep 9, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 9, 2026 | JP Morgan | down | Neutral | Underweight |
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dyne-tx.com
News
- Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32
- Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial
- Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36
Your note
Sign in to keep a note on DYN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BESKROVNAYA OXANA | Officer | Sale | Mar 10, 2025 | 195,840 |
| COX JOHN | Chief Executive Officer | Sale | Sep 7, 2026 | 429,507 |
| FRIEDL-NADERER JOHANNA | Officer | Sale | Sep 7, 2026 | 152,897 |
| KERR DOUGLAS | Officer | Stock Award(Grant) | Oct 19, 2026 | 170,564 |
| KERSTEN DIRK | Director | Sale | Jul 26, 2026 | 0 |
| LUBNER DAVID CHARLES | Director | Stock Gift | Apr 23, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.55% | 30,912,287 | 515.62M | Jun 29, 2026 |
| Blackrock Inc. | 6.64% | 12,404,330 | 206.90M | Jun 29, 2026 |
| Jupiter Topco LLC | 6.42% | 11,997,738 | 200.12M | Jun 29, 2026 |
| FMR, LLC | 6.00% | 11,207,000 | 186.93M | Jun 29, 2026 |
| State Street Corporation | 3.99% | 7,458,263 | 124.40M | Jun 29, 2026 |
| Orbis Allan Gray Ltd | 3.75% | 7,006,542 | 116.87M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3.75% | 7,004,602 | 116.84M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 2.46% | 4,602,629 | 76.77M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.39% | 4,471,727 | 74.59M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.33% | 4,349,704 | 72.55M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.13% | 3,986,208 | 66.49M | Sep 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 2.04% | 3,809,721 | 63.55M | Jun 29, 2026 |